Document Detail

No HOPE without proof: do ARBs meet the standard for cardiovascular protection?
MedLine Citation:
PMID:  18449379     Owner:  NLM     Status:  MEDLINE    
Blockade of the renin-angiotensin system (RAS) by angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) plays an important role in the protection and prevention of cardiovascular disease. The Heart Outcomes Prevention Evaluation (HOPE) study established the significant effect of ACE inhibition on cardiovascular morbidity and mortality beyond blood pressure control. Smaller studies have demonstrated the efficacy of ARBs. In addition, a recent analysis from the Blood Pressure Lowering Treatment Trialists' Collaboration showed that ARB-based and ACE inhibitor-based treatment regimens were comparable in terms of the odds ratio for stroke and heart failure, independent of blood pressure reduction. There is an emerging body of evidence to suggest that a combination approach to RAS blockade with an ARB and an ACE inhibitor may further improve cardiovascular outcome compared with monotherapy with either agent alone. The large-scale ONgoing Telmisartan Alone or in combination with Ramipril Global Endpoint Trial (ONTARGET), comparing high-dose ramipril (HOPE study dosage) with telmisartan or a combination of the two, should provide important insight into the benefits of RAS blockade intervention. The results of ONTARGET are anticipated to be available in 2008.
Peter Sleight; Anne Jakobsen; Jose Heroys; Ann Ralph; Tomas Rees; Michael Shaw
Related Documents :
20111009 - Effects of renin-angiotensin system inhibition on left atrial function of hypertensive ...
12864879 - Ace inhibition is effective and renoprotective in hypertensive nephrosclerosis: the afr...
8285179 - Angiotensin-converting enzyme inhibitors: more different than alike? focus on cardiac p...
2228559 - Oxygen free radical scavenger system intermediates in essential hypertensive patients b...
15723969 - Effect of treatment with candesartan or enalapril on subcutaneous small artery structur...
2988839 - Angiotensin converting enzyme inhibition does not prevent development of acth-induced h...
5559629 - Modification of the reflex response to stimulation of carotid sinus baroreceptors durin...
24589529 - Validation of the thermor bios bd215 device for home blood pressure measurement accordi...
9249119 - Maternal and fetal effects of isoproterenol in the gravid ewe.
Publication Detail:
Type:  Journal Article; Meta-Analysis; Review     Date:  2008-03-26
Journal Detail:
Title:  Medscape journal of medicine     Volume:  10 Suppl     ISSN:  1934-1997     ISO Abbreviation:  Medscape J Med     Publication Date:  2008  
Date Detail:
Created Date:  2008-05-01     Completed Date:  2008-06-05     Revised Date:  2013-06-05    
Medline Journal Info:
Nlm Unique ID:  101462763     Medline TA:  Medscape J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S6     Citation Subset:  IM    
Department of Cardiovascular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin II Type 1 Receptor Blockers / administration & dosage*
Angiotensin-Converting Enzyme Inhibitors / administration & dosage*
Cardiotonic Agents / administration & dosage*
Cardiovascular Diseases / mortality*,  prevention & control*
Clinical Trials as Topic / statistics & numerical data*
Evidence-Based Medicine / statistics & numerical data
Practice Guidelines as Topic*
Treatment Outcome
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Cardiotonic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cardiovascular high-risk patients--treat to protect, but whom?
Next Document:  Cardiac and vascular protection: the potential of ONTARGET.